Physician profile
Christopher Duke
NPI 1942225396
$1,187.53
in general payments reported to CMS, 2019-2025
21 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $75.14 · 2021: $65.72 · 2022: $121 · 2023: $120 · 2024: $238 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $206.23 | 2019-2025 | |
| Aerin Medical INC. | $143.84 | 2025 | |
| Corcept Therapeutics | $128.55 | 2024 | Korlym |
| Mentor Worldwide LLC | $120.55 | 2019 | |
| Amgen INC. | $117.18 | 2019-2020 | |
| Abbvie INC. | $103.94 | 2021-2022 | |
| Astellas Pharma US INC | $46.07 | 2019 | |
| Amarin Pharma, INC. | $44.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $32.80 | 2022 | |
| Viiv Healthcare Company | $30.37 | 2024 | Apretude |
| Allergan, INC. | $24.44 | 2019-2020 | |
| Abbott Laboratories | $23.83 | 2023 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $21.68 | 2019 | |
| Idorsia Pharmaceuticals US INC | $21.59 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $21.07 | 2023 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.77 | 2025 | Zepbound |
| Astrazeneca Pharmaceuticals Lp | $20.10 | 2019 | |
| Esperion Therapeutics, INC. | $17.74 | 2021 | |
| Sanofi Pasteur INC. | $17.15 | 2023 | |
| Tactile Systems Technology INC | $13.83 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.